低剂量乙酰水杨酸不会改变初产妇的血管反应性。

Low-dose acetylsalicylic acid does not modify maternal vascular reactivity in nulliparas.

机构信息

Department of Women's, Child and Adolescent Health, Federal University of Ceará (UFC), Fortaleza-CE, Brazil.

Department of Nursing, Fortaleza University (UNIFOR), Fortaleza-CE, Brazil.

出版信息

J Matern Fetal Neonatal Med. 2022 Dec;35(25):6029-6035. doi: 10.1080/14767058.2021.1904392. Epub 2021 Mar 26.

DOI:10.1080/14767058.2021.1904392

PMID:33769174

Abstract

OBJECTIVE

To assess if the low-dose acetylsalicylic acid (ASA) would be capable of modifying endothelial function throughout pregnancy in nulliparous patients.

METHODS

A double-blind, randomized clinical trial with 277 were included. A total of 139 were orally administered 100 mg/day of ASA, and 138 received placebo. Endothelial function was assessed by flow-mediated dilation (FMD) in the brachial artery before the start of medication (11-14 weeks) and 20-24 and 30-34 weeks of gestation. The intervention was maintained until 34 weeks. The Mann-Whitney test was used to compare the placebo and ASA groups. The comparison of FMD during pregnancy was performed using the Friedman test.

RESULTS

The groups (ASA and placebo) were similar regarding to age, weight, height, and body mass index (BMI) ( > .005). The comparison of values of FMD (%) between placebo vs. ASA at 11 and 14 weeks (8.9 vs. 9.7%, : .253), 20 and 24 weeks (8.8 vs. 10.7%, : .152), and 30 and 34 weeks (10.7 vs. 9.8%, : .314) did not show significant changes throughout pregnancy. We observed a significant prevalence of PE in the placebo regarding to ASA group [14 (10.2%) vs. 8 (5.8%), : .171].

CONCLUSION

Acetylsalicylic acid did not modify the endothelial function assessed by FMD of the brachial artery during pregnancy in nulliparous women.

摘要

目的

评估低剂量乙酰水杨酸（ASA）是否能够改变初产妇孕期的内皮功能。

方法

这是一项双盲、随机临床试验，共纳入 277 名患者。其中 139 名患者口服 100mg/天的 ASA，138 名患者服用安慰剂。在开始用药前（11-14 周）和妊娠 20-24 周及 30-34 周时，通过肱动脉血流介导的舒张（FMD）评估内皮功能。干预持续至 34 周。采用曼-惠特尼检验比较安慰剂组和 ASA 组。采用弗里德曼检验比较孕期 FMD 的变化。

结果

ASA 组和安慰剂组在年龄、体重、身高和体重指数（BMI）方面无差异（ > .005）。安慰剂组和 ASA 组在 11 周和 14 周（8.9%比 9.7%，：.253）、20 周和 24 周（8.8%比 10.7%，：.152）以及 30 周和 34 周（10.7%比 9.8%，：.314）时 FMD（%）的比较值无显著差异。我们观察到安慰剂组中 PE 的发生率明显高于 ASA 组[14 例（10.2%）比 8 例（5.8%），：.171]。